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weekly up to 100 days post-alloHSCT. Circulating myeloid
(CD11chi) and plasmacytoid (CD123hi) DCs were enumerated and
the expression of CMRF-44 was assessed on CD11chi DC by four
colour ﬂow cytometry. Multivariate analyses were performed using
a non-parametric Mann-Whitney U-test and receiver operating
characteristic (ROC) curves. Following alloHSCT, the severity of
acute GVHD correlated with the number of total DC in the blood
(P  .035). Furthermore, low myeloid and plasmacytoid DC num-
bers were signiﬁcantly associated with grade 2-4 acute GVHD
(P  .046 and .017 respectively). In 40 alloHSCT patients, 27
developed acute GVHD. CMRF-44 was expressed on CD11c
DC in all cases prior to the onset of acute GVHD. Of the 13
patients without GVHD, 8 had no circulating CMRF-44
CD11cDC. CMRF-44 expression was independent of the recon-
stitution of myeloid DC (P  .73). Patients who had CMRF-44
CD11c DC in more than 20% of their post-transplant monitor-
ing samples were more likely to develop acute GVHD (P  .001,
OR  37.1). In addition, patients with more severe grade 2-4
GVHD had signiﬁcantly higher percentages of CMRF-44
CD11c DCs (P  .001). CMRF-44 expression at greater than or
equal to 12% of CD11chi DCs had a sensitivity of 87.5 for predic-
tion of grade 2-4 acute GVHD and a speciﬁcity of 91.7. We
conclude that CMRF-44 expression on blood CD11c DC is
highly associated with the onset of acute GVHD. The detection of
circulating activated DCs may be used as a predictive tool to
identify patients at risk of severe GVHD and potentially to direct
therapy. Our data also reinforces the potential for suitably engi-
neered CMRF-44 or other antibodies directed at DC activation
antigens to prevent or treat GVHD.
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DETERMINING PROGNOSIS FOR PATIENTS WITH ACUTE GVHD IN REAL
TIME: DEVELOPMENT AND TESTING OF AN ACUTE GVHD ACTIVITY
INDEX
McDonald, G.B.1, Leisenring, W.M.1, Martin, P.J.1 1Fred Hutchinson
Cancer Research Center, Seattle, WA.
The current scoring systems for acute GVHD are problematic
due to the retrospective assignment of scores, lack of consideration
for the efﬁcacy of treatment, and inter-observer error. An evi-
dence-based, real-time system for scoring GVHD would be useful
for determining prognosis in individual patients and for quantify-
ing the burden of GVHD across time.Methods:We examined the
severity of signs and symptoms of GVHD from its onset to day 100
in 386 patients with CML who underwent allogeneic transplant
after a myeloablative regimen. During each 10 day period to day
100, a unique letter designation was assigned for each degree of
abnormality in skin, liver, upper gastrointestinal tract, lower gas-
trointestinal tract, immunosuppressive drugs, fever, and perfor-
mance status, respectively. We used a training data set of 193
randomly selected patients, logistic regression methods, and re-
ceiver-operator curves for optimizing the model, to create an
activity index (aGVHDAI) that predicts non-relapse mortality at
day 200. Scaling was carried out by dividing the coefﬁcients in the
logistic regression model by the sum of the coefﬁcients and mul-
tiplying this proportion by 100. The ﬁnal aGVHDAI was then
applied to an independent, 193-patient data set, testing the accu-
racy of the index to predict day 200 non-relapse mortality. Results:
Parameters entering the optimal aGVHDAI model included the
level of jaundice, caloric intake, need for prednisone therapy, and
performance score. Skin GVHD, volume of diarrhea, and presence
of fever did not improve the model’s predictive ability (Table 1).
The area under a receiver-operator curve for the ﬁnal average
aGVHDAI model in the training data set, using non-relapse mor-
tality at day 200 as the end point, was 0.87. When the model was
then applied to an independent data set of 193 patients, the area
under an ROC curve was 0.85. Using the same aGVHD activity
index parameters, a graphic was developed that allows prediction of
non-relapse mortality at day 200 (on the vertical axis) for individual
patients, based on the aGVHDAI at any point in time after trans-
plant (on the horizontal axis). Conclusions: An acute GVHD
activity index has been tested that allows prediction of non-relapse mor-
tality in real-time and provides investigators with a research tool for
assessing the burden of acute GVHDover time. This aGVHDAI, scaled
from 0-100, is based on serum bilirubin levels, caloric intake, need for
prednisone therapy, and performance status.
Table 1. Components of the Acute GVHD Activity Index with
Weighting Factors for Each component
Factor Scoring Level
Scaled Weight-
ing Factor
Liver dys-
function
Total serum bilirubin 2–4 mg/
dL
16
Total serum bilirubin >5 mg/
dL
26
Upper GI
tract
Oral caloric intake <40%, with
poorly controlled anorexia,
nausea, or vomiting
20
Immuno-
suppressive
therapy
Any prednisone dose or
secondary therapy for
GVHD
17
Performance
status
Ambulatory but restricted in
strenuous activity
20
Limited self-care, more than
50% of time in bed, or worse
37
The scale is from 0 to 100, with the end point of day 200 non-
relapse mortality.
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THE CYTOKINE STORM AND ACUTE GRAFT-VERSUS-HOST DISEASE
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NEIC STEM CELL TRANSPLANTATION (allo-SCT)
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The use of RIC regimens has modiﬁed the natural history of
transplant-related complications, especially aGVHD. The aim of
this study was to investigate the role of inﬂammatory cytokines on
aGVHD incidence and severity in 113 patients who received a RIC
allo-SCT from an HLA-identical sibling. Plasma levels of 10 dif-
ferent cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, IL-18,
TNF-
, IFN-
, IFN-, and Fas-L) were measured by ELISA
prior to allo-SCT, at day 0 prior to graft infusion, and at regular
times within the ﬁrst 3 months after allo-SCT. Except for IL-
12p70, all measured cytokines showed little variations in the blood
in the ﬁrst three months after allo-SCT. The incidence of grade
II-IV aGVHD was 45% (95% CI, 36-54%; median onset, 32 days
after allo-SCT). In the subgroup of patients for whom all tested
cytokines could be measured closely, but rigorously prior to
aGVHD clinical onset, a high IL-12p70 level (P  104) was
signiﬁcantly associated with the development of clinically signiﬁ-
cant grade II-IV aGVHD. IL-12p70 levels were signiﬁcantly cor-
related to the severity of aGVHD: grade 0-I, median 468 pg/ml;
grade II, median 2538 pg/ml; and grade III-IV, median 4615
pg/mL (P  .0001). In patients experiencing grade II-IV aGVHD,
IL-12p70 levels decreased after aGVHD therapy. Interestingly, we
found a more rapid recovery of monocytes, the main pool of
IL-12p70-secreting myeloid dendritic cells (DC), prior to aGVHD
clinical onset in patients with grade II-IV aGVHD, as compared to
patients with grade 0-I aGVHD (median, 829/L vs. 552/L; P 
.005). At the effector level, we observed a signiﬁcantly more robust
recovery of genuine naive CD3CD4CD45RACD27 T
cells prior to aGVHD clinical onset, in patients with grade II-IV
aGVHD, as compared to patients with grade 0-I aGVHD (median,
50/L vs. 16/L; P  .006). In multivariate analysis, IL-12p70
level measured before aGVHD clinical onset was the strongest
predictive factor for aGVHD development and severity (P 104;
RR  10.7; 95% CI, 3.8-30.6). Overall, these ﬁndings reconstitute
a genuine Th1 loop, supporting a model where aGVHD primarily
reﬂects a type 1 alloreaction (rapid monocytes/DC recovery, IL-
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